Shares of Bio-Rad Laboratories BIO moved higher by 2.0% in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share increased 72.84% year over year to $4.01, which beat the estimate of $3.29.
Revenue of $789,839,000 up by 26.49% from the same period last year, which beat the estimate of $686,800,000.
Looking Ahead
Bio-Rad Sees FY21 Adj. Currency-Neutral Sales Growth 4.5-5% Year Over Year
Details Of The Call
Date: Feb 11, 2021
Time: 06:00 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/8cfv55c7
Technicals
52-week high: $648.39
Company's 52-week low was at $309.38
Price action over last quarter: Up 9.79%
Company Overview
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (60% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the United States (40% of 2019 sales), Europe (33%), and Asia (22%), with Canada and Latin America accounting for the bulk of the remaining 5%. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.